VIVEVE MEDICAL INC (VIVE) Stock Price, Quote, News and Overview
NASDAQ:VIVE - Nasdaq - US92852W5013 - Common Stock - Currency: USD
VIVE Quote, Performance and Key Statistics
0.2201
-0.04 (-15.35%)
The current stock price of VIVE is 0.2201 USD. In the past month the price decreased by -51.09%. In the past year, price decreased by -78.42%.
VIVE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About VIVE
Company Profile
Viveve Medical, Inc. engages in the design, development, manufacture, and marketing of platform medical technology. The company is headquartered in Englewood, Colorado and currently employs 47 full-time employees. The firm's CMRF technology is delivered through a radiofrequency (RF) generator, handpiece and treatment tip, that collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI), which is known as Viveve treatment. The Viveve System uses a method of delivering monopolar radiofrequency (RF) energy for treating tissue, such as Monopolar Radiofrequency Energy. The Viveve System also uses a cryogen surface cooling that enables volumetric heating of vaginal tissue. The Viveve System also uses a proprietary, controlled cryogen surface cooling that enables deep volumetric heating of vaginal tissue. The firm's subsidiary includes Viveve, Inc. and Viveve BV.
Company Info
VIVEVE MEDICAL INC
345 Inverness Dr S Bldg B Ste 250
Englewood COLORADO 80112 US
CEO: Scott Durbin
Employees: 47
Company Website: https://us.viveve.com/
Phone: 14085301900.0
VIVEVE MEDICAL INC / VIVE FAQ
What is the stock price of VIVEVE MEDICAL INC today?
The current stock price of VIVE is 0.2201 USD. The price decreased by -15.35% in the last trading session.
What is the ticker symbol for VIVEVE MEDICAL INC stock?
The exchange symbol of VIVEVE MEDICAL INC is VIVE and it is listed on the Nasdaq exchange.
On which exchange is VIVE stock listed?
VIVE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VIVEVE MEDICAL INC stock?
8 analysts have analysed VIVE and the average price target is 4.77 USD. This implies a price increase of 2066.52% is expected in the next year compared to the current price of 0.2201. Check the VIVEVE MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VIVEVE MEDICAL INC worth?
VIVEVE MEDICAL INC (VIVE) has a market capitalization of 2.36M USD. This makes VIVE a Nano Cap stock.
How many employees does VIVEVE MEDICAL INC have?
VIVEVE MEDICAL INC (VIVE) currently has 47 employees.
Is VIVEVE MEDICAL INC (VIVE) expected to grow?
The Revenue of VIVEVE MEDICAL INC (VIVE) is expected to grow by 7.41% in the next year. Check the estimates tab for more information on the VIVE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VIVEVE MEDICAL INC (VIVE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VIVE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VIVE, evaluating the profitability, health, valuation and growth aspects
- VIVEVE MEDICAL INC (VIVE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VIVEVE MEDICAL INC (VIVE) Sales and EPS estimates to see what analysts future expectations are.
- VIVEVE MEDICAL INC (VIVE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VIVEVE MEDICAL INC (VIVE) Insider and Institutional Ownership to learn about the owners and their transactions.
- VIVEVE MEDICAL INC (VIVE) Stock Chart to make your own analysis
- VIVEVE MEDICAL INC (VIVE) Latest news and press-releases to stay up to date.
Does VIVEVE MEDICAL INC (VIVE) stock pay dividends?
VIVE does not pay a dividend.
When does VIVEVE MEDICAL INC (VIVE) report earnings?
VIVEVE MEDICAL INC (VIVE) will report earnings on 2023-03-15.
What is the Price/Earnings (PE) ratio of VIVEVE MEDICAL INC (VIVE)?
VIVEVE MEDICAL INC (VIVE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.65).
What is the Short Interest ratio of VIVEVE MEDICAL INC (VIVE) stock?
The outstanding short interest for VIVEVE MEDICAL INC (VIVE) is 0.03% of its float. Check the ownership tab for more information on the VIVE short interest.
VIVE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VIVE. When comparing the yearly performance of all stocks, VIVE is a bad performer in the overall market: 98.42% of all stocks are doing better.
VIVE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VIVE. VIVE may be in some trouble as it scores bad on both profitability and health.
VIVE Financial Highlights
Over the last trailing twelve months VIVE reported a non-GAAP Earnings per Share(EPS) of -2.65. The EPS increased by 32.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
VIVE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to VIVE. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 7.44% and a revenue growth 7.41% for VIVE